12:00 AM
 | 
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Asunaprevir: Phase IIa data

Data from 32 treatment-naïve, non-cirrhotic patients with HCV genotype 1 infection in Part 1 of an open-label, international Phase IIa trial showed that all patients who received an all oral regimen of asunaprevir, daclatasvir and BMS-791325 for 12 (n=16) or 24 weeks (n=16) had HCV RNA levels <25 IU/mL by week 4 of treatment and there were no virologic breakthroughs or relapses. At treatment week 12,...

Read the full 317 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >